Replies to post #91347 on Amarantus Bioscience Holdings Inc (AMBS)

[seebisquick]

"We continue to believe that adding a Phase 2 asset to our therapeutics pipeline will significantly build near-term shareholder value"

This also stuck out to me, I was wondering how the PD-LID in-license would significantly bolster shareholder value in the near-term, besides just being another 'iron in the fire'.

I do like the fact that it would be near-term value, according to Gerald.